Patents by Inventor Jason S. Simon

Jason S. Simon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
    Patent number: 11598776
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: March 7, 2023
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF THYROID AND KIDNEY CANCER SUBJECTS TO LENVATINIB COMPOUNDS
    Publication number: 20180209980
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
    Patent number: 9945862
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: April 17, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF THYROID AND KIDNEY CANCER SUBJECTS TO LENVATINIB COMPOUNDS
    Publication number: 20140187577
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: July 3, 2014
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • GENETIC MARKERS ASSOCIATED WITH INTERFERON-ALPHA RESPONSE
    Publication number: 20130251677
    Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.
    Type: Application
    Filed: May 30, 2013
    Publication date: September 26, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Arthur Bertelsen, Jacques Fellay, Dongliang Ge, David B. Goldstein, John G. McHutchison, Ping Qiu, Kevin Shianna, Jason S. Simon, Alexander J. Thompson, Thomas Urban
  • Genetic markers associated with interferon-alpha response
    Patent number: 8535887
    Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: September 17, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Arthur Bertelsen, Jacques Fellay, Dongliang Ge, David B. Goldstein, John G. McHutchison, Ping Qiu, Kevin Shianna, Jason S. Simon, Alexander J. Thompson, Thomas Urban
  • Antibodies and functional fragments thereof that specifically bind an RF-amide peptide or a precursor thereof
    Patent number: 8133980
    Abstract: The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: March 13, 2012
    Assignee: Schering Corporation
    Inventors: Ying Jiang, Fang Liang Zhang, Nicholas J. Murgolo, Lin Luo, Jason S. Simon
  • BRAF BIOMARKERS
    Publication number: 20110158944
    Abstract: The present invention provides, inter alia, methods for predicting the sensitivity of a disease, such as cancer, to an ERK1 or ERK2 or MEK inhibitor by detecting the presence of an allele of BRAF in cells mediating the disease. Methods of treatment are also provided.
    Type: Application
    Filed: November 26, 2008
    Publication date: June 30, 2011
    Inventors: Thomas J. Hosted, Jason S. Simon, Marc M. Delorenzo, Donna Marie Carr, William T. Windsor, Ahmed A. Samatar
  • G-PROTEIN COUPLED RECEPTOR LIGANDS AND METHODS
    Publication number: 20110020354
    Abstract: The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
    Type: Application
    Filed: October 1, 2010
    Publication date: January 27, 2011
    Inventors: Ying Jiang, Fang Liang Zhang, Nicholas J. Murgolo, Lin Luo, Jason S. Simon
  • GENETIC MARKERS ASSOCIATED WITH INTERFERON-ALPHA RESPONSE
    Publication number: 20100297080
    Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers arc useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.
    Type: Application
    Filed: May 21, 2010
    Publication date: November 25, 2010
    Inventors: ARTHUR BERTELSEN, JACQUES FELLAY, DONGLANG GE, DAVID GOLDSTEIN, JOHN G. MCHUTCHISON, NICHOLAS J. MURGOLO, PING QIU, ROBERT ORVILLE RALSTON, II, KEVIN SHIANNA, JASON S. SIMON, ALEXANDER J. THOMPSON, THOMAS URBAN
  • G-protein coupled receptor ligands and methods
    Patent number: 7807390
    Abstract: The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
    Type: Grant
    Filed: January 7, 2008
    Date of Patent: October 5, 2010
    Assignee: Schering Corporation
    Inventors: Ying Jiang, Fang Liang Zhang, Nicholas J. Murgolo, Lin Luo, Jason S. Simon
  • G-PROTEIN COUPLED RECEPTOR LIGANDS AND METHODS
    Publication number: 20080138348
    Abstract: The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
    Type: Application
    Filed: January 7, 2008
    Publication date: June 12, 2008
    Inventors: Ying Jiang, Fang Liang Zhang, Nicholas J. Murgolo, Lin Luo, Jason S. Simon
  • G-protein coupled receptor ligands and methods
    Patent number: 7338772
    Abstract: The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: March 4, 2008
    Assignee: Schering Corporation
    Inventors: Ying Jiang, Fang Liang Zhang, Nicholas J. Murgolo, Lin Luo, Jason S. Simon
  • G-protein coupled receptor ligands and methods
    Publication number: 20030223992
    Abstract: The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
    Type: Application
    Filed: April 10, 2003
    Publication date: December 4, 2003
    Applicant: Schering Corporation
    Inventors: Ying Jiang, Fang Liang Zhang, Nicholas J. Murgolo, Lin Luo, Jason S. Simon